Post-colonoscopy colorectal cancer in inflammatory bowel diseases.

Dr Nick Burr, Prof. Matthew Rutter, Andy Smith, Simon Whalley, Jon Shelton, Clare Pearson, Prof. Eva Morris, Dr Roland Valori.
Outline

• Background
  – CRC in IBD
  – Surveillance in IBD
  – PCCRC in IBD
    • WEO definitions of interval cancers

• Results
  – 1 year, 3-year
  – Comparison of characteristics and rates – TP v FN
  – Comparison of outcomes – detected v PCCRC
    • Stage
    • Emergency presentation
Colorectal cancer in inflammatory bowel disease

- Incidence of IBD increasing
- CRC is a serious complications
- Patients worry about developing cancer (de Rooy 2001)
- There is uncertainty about current risk:
  1. Stable risk over time – 60% increase from general population. (Herrington 2012)
  2. Similar pooled risk to general population, 50% increased risk for selected individuals. (Jess 2012)
- Methods to improve outcomes
  - Colonoscopic surveillance
  - Surgery
Comparing non-IBD and IBD associated CRC

- UK population datasets (2005 – 2013):
  - Cancer Registry (NCRAS)
  - HES (IBD admission codes)
- ~130,000 CRC
- 2% with admission code for IBD (CD or UC)
- Comparisons
  - Mean age of 65yrs for IBD and 70yrs for sporadic
  - Increase in emergency presentations for IBD: 19% versus 9%
  - Reduced unadjusted survival for IBD cancer 118 versus 148 months
- No differences for location and stage
Colorectal cancer surveillance in IBD

- Detect pre-cancerous lesions, early cancers and reduce mortality
- British Society of Gastroenterology guidelines \((Cairns, 2010)\)

- Individuals with IBD advised not necessary to participate in the national bowel cancer screening programme
- Low uptake of surveillance guidelines
  - 54% in French population \((Vienne 2011)\)
- Is there a benefit?
Surveillance

- Purpose of surveillance is to reduced mortality from CRC
- Good for detecting dysplasia
  - SCENIC 2015.
  - Chromoendoscopy better than white light.
    - Increased RR 1.8 (95% CI 1.2 – 2.6)
- Low grade dysplasia associated with nine-fold increase in CRC risk *(Systematic review, Thomas 2007)*
- Low overall progression of dysplasia to cancer:
  - 5% at 4 years low grade dysplasia to CRC. *(Zisman 2012)*
- Low risk of CRC for those who defer surgery
  - 2% risk of node negative CRC amongst 175 patients deferring surgery for median of 5 months. *(Murphy 2016)*
- CRC Incidence Rate in pts undergoing CE significantly lower than in those not having CE
  - (2.2 vs 4.6 per 1,000 patient-years); (P =.02). *(Choi, AJG, 2015).*
Benefit of surveillance?

• Cochrane review 2006.
  – No clear survival benefit
  – Earlier stage cancers in the surveillance population.
    • Better prognosis but subject to lead time bias.
• Colonoscopy within 36 months. *(Ananthrakrishnan 2014)*
  – Reduced CRC incidence. OR 0.56 (95% CI 0.39 – 0.80).
  – Reduced mortality rate for those CRC. OR 0.34 (95% CI 0.12 – 0.95).
• Surveillance is not without cost or risk
  – High burden to the patient and healthcare services.
  – Small risk of damage during the procedure.
  – Potential for harm from unnecessary investigations and endoscopic or surgical resections.
  – No cost-effectiveness analyses.
Post-colonoscopy colorectal cancer - PCCRC

- Colorectal cancer occurring after a “negative” colonoscopy
- ~ 7% in England in 2007 for the whole population *(Morris 2014)*
- Key performance indicator of colonoscopy
- PCCRC rate in IBD is high
  - 30% of those in a dedicated surveillance programme. *(Mooiweer 2015)*
  - 39% in a population dataset. *(Le Clercq 2015)*
  - Up to 54% in UC in latest Swedish data. *(Stjärngrim 2017)*
Reasons for PCCRC in IBD

- Lesions:
  - Missed
  - Incomplete resection
  - Rapidly growing

- Patient / procedure:
  - Patient biology
  - Inadequate bowel preparation
  - Endoscopy technique

- IBD
  - Flat lesions
  - Disease activity and inflammation
  - Pseudopolyps
Taxonomy of PCCRC in IBD

- **Interval cancers**
  - Cancer is identified before the next recommended surveillance examination

- **Non-interval cancers**
  - Type A – Cancer identified at the recommended surveillance interval
  - Type B – Cancer identified after the recommended surveillance interval
  - Type C - No subsequent screening was recommended up to 10 years after the index colonoscopy.

- **Type A could be a surveillance success**
  - but may also have been a missed opportunity at the earlier test.

- **Interval cancers could be considered a surveillance failure and therefore an indicator of poor quality surveillance**

- **The non-interval cases may indicate recommended surveillance intervals need to change**
## 4 case examples in IBD

<table>
<thead>
<tr>
<th>Interval type</th>
<th>Type A</th>
<th>Non-interval type</th>
<th>Type B</th>
<th>Type C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detected before recommended interval</td>
<td>Detected at recommended interval</td>
<td>Detected after recommended interval</td>
<td>No interval recommended</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical scenario</strong></td>
<td>Quiescent pan-UC.</td>
<td>Pan UC &amp; inflammatory polyps.</td>
<td>Pan-UC &amp; PSC.</td>
<td>Proctitis.</td>
</tr>
<tr>
<td><strong>Recommendation</strong></td>
<td>Surveillance in 5 y.</td>
<td>Surveillance in 3 y.</td>
<td>1 year surveillance.</td>
<td>No surveillance booked.</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td>4 y later anaemia develops; colonoscopy reveals CRC</td>
<td>CRC is found at the repeat test.</td>
<td>Patient misses this, Returns 3 y later with CRC.</td>
<td>Attends 7 years later with weight loss CT reveals CRC</td>
</tr>
<tr>
<td><strong>Possible verdict</strong></td>
<td>The recommended screening/surveillance interval may be too long</td>
<td>The recommended screening/surveillance interval may be too long</td>
<td>Reinforces importance of adherence to recommended screening/surveillance intervals</td>
<td>Review whether subsequent screening/surveillance may have been appropriate</td>
</tr>
</tbody>
</table>
Aims

- Determine PCCRC rates in those with IBD
- Examine potential risk factors
- Explore outcomes for PCCRC and detected cancers.
Methods

- Data sources
  - Colorectal cancer – National Cancer Registration and Analysis Service
  - Colonoscopies – Hospital Episode Statistics
- Cancers diagnosed between 2006 and 2016
- Colonoscopies before the CRC diagnosis
  - True positive test - cancer diagnosed within 6 months
  - Falsely negative test – cancer diagnosed 6 – 36 months
- PCCRC – 3 year rate calculated as:
  \[
  \text{false negative} / (\text{true positive} + \text{false negative}) \%
  \]
- PCCRC-1yr also calculated by varying the intervals above
- We explored factors associated with PCCRC.
Conclusions

- PCCRC rates are high in those with IBD
  - True interval cancers and potentially missed lesions
  - Non-interval cancer which may include successful surveillance tests
- High numbers of stage 4 PCCRC-3yr, which are likely to reflect missed lesions
- Need to investigate avoidable reasons for cancers in IBD
- Further research needed to investigate the efficacy of surveillance in IBD.
  - Who to survey?
  - How often?
  - Which method?
Problems with assessing the efficacy of surveillance

- Unethical to randomise to colonoscopy or not
  - Added to that would need follow up of ~ 10 years

- Retrospective studies
  - Limited by lack of appropriately matched control groups.
  - Surveillance adherence will be associated with “healthy behaviour” and engagement with services. May over estimate the efficacy of surveillance.
What are the key questions/issues?

- Can IBD related CRC be prevented with optimal treatment and surveillance techniques?
- In what way does this data help us optimise our approach?
- What is the optimal management strategy?
  - Who, what and how?
- How can the process be quality assured?
- What role can the WEO play?
Collaborators

- Professor Eva Morris
- Dr Roland Valori
- Professor Matthew Rutter
- Andy Smith
- Simon Whalley
- Jon Shelton
- Clare Pearson
This work is supported by Cancer Research UK C23434/A23706.

It uses data provided by patients and collected by the NHS as part of their care and support.

These data are collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England (PHE). Access to these data was facilitated by the PHE Office for Data Release.

Dr Burr is funded by a grant from Crohn’s and Colitis UK M16/4